However, rates of progressive disease (PD) are high after ICI treatment, with reported PD rates of 41% in nivolumab‐treated squamous (Sq) NSLCL,1 44% in nivolumab‐treated non‐Sq NSCLC,2 and 42% in atezolizumab‐treated unselected NSCLC,4 regardless of tumor PD‐L1 expression, and these rates are consistently worse than those for docetaxel. This evidence concerns the gene CD274 and neoplasm.